Human Chronic Lymphoid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Chronic Lymphoid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated) are primary cells isolated from treatment-naïve CLL patients, providing an unmodified biological system for studying early disease mechanisms and therapeutic responses. These PBMCs contain malignant CD5⁺/CD19⁺/CD23⁺ B-cells with characteristic genetic features such as del(13q), trisomy 12, or IGHV mutation status, along with accompanying immune cells that reflect the tumor microenvironment. Morphologically, these cells are mainly mature small lymphocyte-like, with small and round cell bodies. Their functional abnormalities are mainly manifested in the continuous activation of the B cell receptor (BCR) signaling pathway, which promotes cell survival and high expression of anti-apoptotic proteins (such as BCL-2 family members), which inhibit programmed cell death. In clinical and translational investigations, these samples are widely used to identify CLL-related biomarkers, monitor disease progression, complement routine blood analyses, and support studies of mononuclear cell involvement in human leukemia.